Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

Abstract Treatment outcomes for major depressive disorder (MDD) need to be improved.
Presently, no clinically relevant tools have been established for stratifying subgroups or …

Abstract Treatment-resistant depression (TRD) is a subset of Major Depressive Disorder
which does not respond to traditional and first-line therapeutic options. There are several …

Background Sub-anaesthetic administration of ketamine is an emerging practice in patients
presenting treatment resistant depression (TRD), however several outstanding questions …

This is the first systematic review of the safety of ketamine in the treatment of depression
after single and repeated doses. We searched MEDLINE, PubMed, PsycINFO, and …

Depression is the third leading cause of disability in the world. Depressive symptoms may
be reduced within several weeks after the start of conventional antidepressants, but …

Ketamine was introduced into clinical practice in the 1960s and continues to be both
clinically useful and scientifically fascinating. With considerably diverse molecular targets …

Background Patients with major depression respond to antidepressant treatment, but 10%–
30% of them do not improve or show a partial response coupled with functional impairment …

Traditional antidepressants require many weeks to reveal their therapeutic effects. However,
the widely replicated observation that a single subanesthetic dose of the N-methyl-D …

Objective: The authors conducted a systematic review and meta-analysis of ketamine and
other N-methyl-d-aspartate (NMDA) receptor antagonists in the treatment of major …